Opiant Pharmaceuticals, Inc. (OPNT)’s Chief Financial Officer David O’toole Paid for 3,000 Shares of the Company; Shorts at SUEZ SA ORDINARY SHARES (SZEVF) Raised By 37.45%

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Logo

SUEZ SA ORDINARY SHARES (OTCMKTS:SZEVF) had an increase of 37.45% in short interest. SZEVF’s SI was 990,300 shares in May as released by FINRA. Its up 37.45% from 720,500 shares previously. With 3,000 avg volume, 330 days are for SUEZ SA ORDINARY SHARES (OTCMKTS:SZEVF)’s short sellers to cover SZEVF’s short positions. The SI to SUEZ SA ORDINARY SHARES’s float is 0.29%. It closed at $15.04 lastly. It is down 0.00% since May 16, 2017 and is . It has underperformed by 11.55% the S&P500.

The stock decreased 1.66% or $0.29 during the last trading session, reaching $17.2. About 30,882 shares traded. Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) has risen 144.32% since May 16, 2017 and is uptrending. It has outperformed by 132.77% the S&P500.

More news for Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) were recently published by: Nasdaq.com, which released: “Opiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate Update” on May 08, 2018. Nasdaq.com‘s article titled: “Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for ..” and published on April 18, 2018 is yet another important article.

Opiant Pharmaceuticals Inc Chief Financial Officer and an insider David O’toole recently made a purchase of 3,000 company shares with a total value of $56,550 at the average stock price which was $18.9. The legal document was revealed on 14-05-2018 with the Washington-based Security and Exchange Commission and is now available online here. David O’toole now has ownership of 3,000 shares or 0.11% of Opiant Pharmaceuticals Inc’s market cap.

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company has market cap of $46.39 million. The firm offers NARCAN nasal spray, a treatment to reverse opioid overdoses. It has a 23.12 P/E ratio. The Company’s pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

SUEZ SA, together with its subsidiaries, provides water management, recycling and waste recovery, water treatment, and consulting services. The company has market cap of $8.73 billion. The firm operates in Water Europe, Recycling and Recovery Europe, International, and Other divisions. It has a 26.57 P/E ratio. It provides water distribution and treatment services to individuals, local authorities, and industrial clients; waste collection and treatment services, including collection, sorting, recycling, composting, energy recovery, and landfilling for non-hazardous and hazardous waste for local authorities and industrial clients; and water, waste, and engineering services.